Cyclin A1 Modulates the Expression of Vascular Endothelial Growth Factor and Promotes Hormone-Dependent Growth and Angiogenesis of Breast Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Syed Khaja, Azharuddin Sajid ^a   Dizeyi, Nishtman ^a   Kopparapu, Pradeep Kumar ^a   Anagnostaki, Lola ^b   Härkönen, Pirkko ^c   Persson, Jenny Liao ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN A1; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA ISOLATION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR INVASION; TUMOR VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CYCLIN A1; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84881496777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072210     Document Type: Article

References (50)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, et al. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241. doi:10.3322/caac.21149. PubMed: 22700443.
2. Musgrove EA, Sutherland RL, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643. doi:10.1038/nrc2713. PubMed: 19701242.
3. Roy V, Perez EA, (2009) Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat 116: 31-38. doi:10.1007/s10549-008-0268-y. PubMed: 19101790.
4. Qu Z, Van Ginkel S, Roy AM, Westbrook L, Nasrin M, et al. (2008) Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res 68: 6232-6240. doi:10.1158/0008-5472.CAN-07-5654. PubMed: 18676847.
5. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, et al. (2008) An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 6: 1630-1638. doi:10.1158/1541-7786.MCR-07-2172. PubMed: 18922978.
6. Rydén L, Jönsson PE, Chebil G, Dufmats M, Fernö M, et al. (2005) Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 41: 256-264. doi:10.1016/j.ejca.2004.06.030. PubMed: 15661551.
7. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, et al. (1999) Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149: 29-40. doi:10.1016/S0303-7207(99)00003-9. PubMed: 10375015.
8. Giovannini M, Aldrighetti D, Zucchinelli P, Belli C, Villa E, (2010) Antiangiogenic strategies in breast cancer management. Crit Rev Oncol/Hematol 76: 13-35. doi:10.1016/j.critrevonc.2009.12.004. PubMed: 20702105.
9. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, et al. (2007) The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 96: 541-545. doi:10.1038/sj.bjc.6603487. PubMed: 17164762.
10. Wegiel B, Ekberg J, Talasila KM, Jalili S, Persson JL, (2009) The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia. Leukemia 23: 251-261. doi:10.1038/leu.2008.300. PubMed: 18987662.
11. Chambers AF, Groom AC, MacDonald IC, (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572. doi:10.1038/nrc865. PubMed: 12154349.
12. Yokota J, (2000) Tumor progression and metastasis. Carcinogenesis 21: 497-503. doi:10.1093/carcin/21.3.497. PubMed: 10688870.
13. Hu Z, Li X, Yuan R, Ring BZ, Su L, (2010) Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat 120: 705-714. doi:10.1007/s10549-009-0488-9. PubMed: 19657731.
14. Stein RA, Gaillard S, McDonnell DP, (2009) Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. J Steroid Biochem Mol Biol 114: 106-112. doi:10.1016/j.jsbmb.2009.02.010. PubMed: 19429439.
15. Applanat MP, Buteau-Lozano H, Herve MA, Corpet A, (2008) Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol 617: 437-444. doi:10.1007/978-0-387-69080-3_42. PubMed: 18497067.
16. Weidner N, Semple JP, Welch WR, Folkman J, (1991) Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med 324: 1-8. doi:10.1056/NEJM199101033240101. PubMed: 1701519.
17. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, et al. (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61: 5407-5414. PubMed: 11454684.
18. Shojaei F, (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320: 130-137. doi:10.1016/j.canlet.2012.03.008. PubMed: 22425960.
19. Dienstmann R, Markman B, Tabernero J, (2012) Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol 7: 137-145. doi:10.2174/157488412800228929. PubMed: 22432839.
20. Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, et al. (2012) Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol 70: 251-258. doi:10.1007/s00280-012-1911-1. PubMed: 22744359.
21. Müller-Tidow C, Bornemann C, Diederichs S, Westermann A, Klümpen S, et al. (2001) Analyses of the genomic methylation status of the human cyclin A1 promoter by a novel real-time PCR-based methodology. FEBS Lett 490: 75-78. doi:10.1016/S0014-5793(01)02128-7. PubMed: 11172814.
22. Ekberg J, Holm C, Jalili S, Richter J, Anagnostaki L, et al. (2005) Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome. Eur J Haematol 75: 106-115. doi:10.1111/j.1600-0609.2005.00473.x. PubMed: 16004607.
23. Yang R, Morosetti R, Koeffler HP, (1997) Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res 57: 913-920. PubMed: 9041194.
24. Sweeney C, Murphy M, Kubelka M, Ravnik SE, Hawkins CF, et al. (1996) A distinct cyclin A is expressed in germ cells in the mouse. Development 122: 53-64. PubMed: 8565853.
25. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, et al. (2004) The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A 101: 6478-6483. doi:10.1073/pnas.0401139101. PubMed: 15123840.
26. Wegiel B, Bjartell A, Ekberg J, Gadaleanu V, Brunhoff C, et al. (2005) A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. Oncogene 24: 6385-6393. PubMed: 16007189.
27. Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, et al. (2012) Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 119: 5492-5501. doi:10.1182/blood-2011-07-365890. PubMed: 22529286.
28. Ekberg J, Landberg G, Holm C, Richter J, Wolgemuth DJ, et al. (2004) Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells. Oncogene 23: 9082-9089. doi:10.1038/sj.onc.1208090. PubMed: 15489899.
29. Yang R, Nakamaki T, Lübbert M, Said J, Sakashita A, et al. (1999) Cyclin A1 expression in leukemia and normal hematopoietic cells. Blood 93: 2067-2074. PubMed: 10068680.
30. Liao C, Li SQ, Wang X, Muhlrad S, Bjartell A, et al. (2004) Elevated levels and distinct patterns of expression of A-type cyclins and their associated cyclin-dependent kinases in male germ cell tumors. Int J Cancer 108: 654-664. doi:10.1002/ijc.11573. PubMed: 14696091.
31. Shames DS, Girard L, Gao B, Sato M, Lewis CM, et al. (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLOS Med 3: e486. doi:10.1371/journal.pmed.0030486. PubMed: 17194187.
32. Liao C, Wang XY, Wei HQ, Li SQ, Merghoub T, et al. (2001) Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc Natl Acad Sci U S A 98: 6853-6858. doi:10.1073/pnas.121540098. PubMed: 11381140.
33. Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, et al. (2008) Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst 100: 1022-1036. doi:10.1093/jnci/djn214. PubMed: 18612129.
34. Wegiel B, Bjartell A, Culig Z, Persson JL, (2008) Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 122: 1521-1529. PubMed: 18027847.
35. Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, et al. (2008) Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res 68: 2204-2213. doi:10.1158/0008-5472.CAN-07-3141. PubMed: 18381426.
36. Landberg G, Ostlund H, Nielsen NH, Roos G, Emdin S, et al. (2001) Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Oncogene 20: 3497-3505. doi:10.1038/sj.onc.1204471. PubMed: 11429696.
37. Lodén M, Stighall M, Nielsen NH, Roos G, Emdin SO, et al. (2002) The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21: 4680-4690. doi:10.1038/sj.onc.1205578. PubMed: 12096344.
38. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, et al. (2005) Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 86: 127-141. doi:10.1016/j.ygeno.2005.04.008. PubMed: 15950434.
39. Tomayko MM, Reynolds CP, (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154. doi:10.1007/BF00300234. PubMed: 2544306.
40. Horwitz KB, Zava DT, Thilagar AK, Jensen EM, McGuire WL, (1978) Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res 38: 2434-2437. PubMed: 667841.
41. Hicklin DJ, Ellis LM, (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027. PubMed: 15585754.
42. Jennbacken K, Vallbo C, Wang W, Damber JE, (2005) Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 65: 110-116. doi:10.1002/pros.20276. PubMed: 15880525.
43. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, et al. (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2: 289-300. doi:10.1016/S1535-6108(02)00153-8. PubMed: 12398893.
44. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. doi:10.1038/nm0603-669. PubMed: 12778165.
45. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, et al. (2002) Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 8: 841-849. PubMed: 12091880.
46. Liberato MH, Sonohara S, Brentani MM, (1993) Effects of androgens on proliferation and progesterone receptor levels in T47D human breast cancer cells. Tumour Biol 14: 38-45. doi:10.1159/000217823. PubMed: 8493449.
47. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB, (1994) Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein. Cancer Res 54: 4703-4709. PubMed: 8062268.
48. Modjtahedi H, Komurasaki T, Toyoda H, Dean C, (1998) Anti-EGFR monoclonal antibodies which act as EGF, TGFalpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours. Int J Cancer 75: 310-316. doi:10.1002/(SICI)1097-0215(19980119)75:2. PubMed: 9462724.
49. Dickson RB, Bates SE, McManaway ME, Lippman ME, (1986) Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res 46: 1707-1713. PubMed: 2418952.
50. Lapointe J, Labrie C, (2001) Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 142: 4331-4338. doi:10.1210/en.142.10.4331. PubMed: 11564693.